p.AI
p.AI, founded in 2020, addresses the challenges in the pharmaceutical industry, particularly pharmacovigilance, by offering automated solutions. Their primary product, L2AI software, is designed to automatically process a large volume of Eudravigilance L2A adverse event reports, from download to upload into customer databases. The company leverages expertise in data science and pharmacovigilance, combining advanced analytics like machine learning and active learning to ensure high compliance and efficiency. L2AI aims to increase analysis quality and reduce costs by up to 50% through automation, error prevention, and continuous learning. p.AI focuses on bringing together data science experts and pharmacovigilance professionals to develop validated, high-performance software solutions for the pharmaceutical sector, ensuring high quality standards and customer-centered development.
p.AI
p.AI, founded in 2020, addresses the challenges in the pharmaceutical industry, particularly pharmacovigilance, by offering automated solutions. Their primary product, L2AI software, is designed to automatically process a large volume of Eudravigilance L2A adverse event reports, from download to upload into customer databases. The company leverages expertise in data science and pharmacovigilance, combining advanced analytics like machine learning and active learning to ensure high compliance and efficiency. L2AI aims to increase analysis quality and reduce costs by up to 50% through automation, error prevention, and continuous learning. p.AI focuses on bringing together data science experts and pharmacovigilance professionals to develop validated, high-performance software solutions for the pharmaceutical sector, ensuring high quality standards and customer-centered development.